Nothing said here yet.
to join the conversation.
| Meister Keith A.Director | Sell | 100,650 | $22.0M | Fri, Sep 4 |
| Meister Keith A.Director | Sell | 11,351 | $2.5M | Fri, Sep 4 |
| Meister Keith A.Director | Sell | 7,500 | $1.6M | Fri, Sep 4 |
| Meister Keith A.Director | Sell | 14,196 | $3.1M | Thu, Sep 3 |
| Meister Keith A.Director | Sell | 13,717 | $3.0M | Thu, Sep 3 |
| Meister Keith A.Director | Sell | 13,261 | $2.9M | Thu, Sep 3 |
| Meister Keith A.Director | Sell | 9,961 | $2.2M | Thu, Sep 3 |
| Meister Keith A.Director | Sell | 9,721 | $2.1M | Thu, Sep 3 |
| Meister Keith A.Director | Sell | 8,439 | $1.8M | Thu, Sep 3 |
| Meister Keith A.Director | Sell | 6,656 | $1.5M | Thu, Sep 3 |
| Meister Keith A.Director | Sell | 57,488 | $12.3M | Wed, Sep 2 |
| Meister Keith A.Director | Sell | 10,620 | $2.3M | Wed, Sep 2 |
Shares of genomics company Illumina (NASDAQ:ILMN) fell 17.7% in the afternoon session after the company reported third-quarter 2026 financial results and highlighted impacts from being placed on China's Unreliable Entities List.
Ark Invest increased its exposure to several widely followed biotechnology stocks during the session.
Illumina has delivered a powerful move over the past few years, yet the recent pullback puts fresh focus on a simple question for anyone looking at the stock today: do the cash flows behind the business line up with the current share price?
Jacob Thaysen says Illumina delivered a strong third quarter, beat expectations and raised its fourth-quarter outlook.
Illumina (ILMN) has released its third quarter results, reporting US$1.13b in revenue and net income of US$220m, and has raised its full-year 2026 revenue outlook to a range of US$4.64b to US$4.66b.
Clinical sequencing demand drives margin expansion and full-year guidance hikes.
Boost ROI with cloud-based AI, genomic data integration, variant interpretation, predictive analytics and custom knowledge modeling for precision medicine and drug discovery.Dublin, Oct.
Players: Roche, Thermo Fisher, IQVIA, Labcorp, Eurofins. Profiled: gene-panel design, harmonization, interpretation, reporting, technologies, applications and regions.Dublin, Oct.
Key TakeawaysIllumina shares fell 13% after third-quarter revenue of $1. 13 billion missed consensus, even though adjusted EPS beat and full-year guidance went up.
Illumina stock crashed Friday, despite beating third-quarter expectations, on tariff confusion and a shaky backdrop for AI-tied tech names.
Illumina raises its 2026 guidance as strong clinical sequencing demand and NovaSeq X adoption fuel growth despite research weakness and pricing pressures.
Moby summary of Illumina, Inc.'s Q3 2026 earnings call